Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05124080 · ClinicalTrials.gov registry record · Early Phase 1
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05124080 is a Early Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants.
The verdict
NCT05124080, a Early Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
. An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis. Twenty adult patients with nail psorasis and skin disease qualifying for a systemic agent per investigator will be treated with deucravacitinib 6 mg daily. Subjects will be assessed for a total of 48 weeks. Psoriasis assessments such as the modified Nail Psoriasis Severity Index will be conducted. Photos will be used to document nail involvement. Descriptive statistical analysis will be conducted at the conclusion of the study.
Interventions
- DRUG Deucravacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05124080
The ClinicalTrials.gov registry entry for NCT05124080 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deucravacitinib is the first listed.
NCT05124080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05124080 about?
NCT05124080 is a clinical study titled "An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis". . An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis. Twenty adult patients with nail psorasis and skin disease qualifying for a systemic agent per investigator will be treated with deucravacitinib 6 mg daily. Su...
What is the current status of trial NCT05124080?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2024-03-01. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT05124080?
The interventions under investigation include: Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05124080?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.